China Medical System Holdings (HK:0867) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
China Medical System Holdings has announced the approval of its ruxolitinib phosphate cream for treating non-segmental vitiligo in Hong Kong. This novel treatment offers a new option for the approximately 75,000 vitiligo patients in Hong Kong, providing hope for those struggling with this chronic skin condition. The cream’s approval in various regions reflects its effectiveness and safety, as demonstrated in global clinical studies.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.